Newsroom | 4130 results

SEATTLE & HEIDELBERG, Deutschland--(BUSINESS WIRE)--AGC Biologics, Ihr kompetenter CDMO-Experte, gab heute eine Vereinbarung über Entwicklungs- und Fertigungsdienstleistungen mit dem Spezialimpfstoffhersteller Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) bekannt, wonach AGC Biologics in seinem Werk in Heidelberg den Wirkstoff für einen vierwertigen Shigella-Biokonjugat-Impfstoff in der klinischen Entwicklung liefern wird. Valneva hat die exklusive Lizenz für den Impfstoffkandidaten von LimmaT...

SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO’s Heidelberg facility. Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which previously worked with AGC Biologics to establish GMP...

LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. (“AvenCell”), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership...

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry. The newly raised capital will...

LYON, France--(BUSINESS WIRE)--MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Oncology...

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Leveragen, a Boston-based biotechnology company pioneering next-generation in vivo antibody discovery platforms, announced today a strategic collaboration with Propeller Bio, a newly launched biotechnology company focused on antibody and protein-based therapeutics. As part of the partnership, Propeller Bio will support the continued development of Leveragen’s antibody discovery platforms through a strategic investment. In turn, Propeller wi...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strategic corporate reorganization and pipeline prioritization aimed at maximizing near-term value, extending operational runway into the second quarter of 2027, and positioning the company for sustained long-term growth. The restructuring and reprioritiz...

CAMBRIDGE, Mass. & HONOLULU--(BUSINESS WIRE)--KOMO Biosciences, a pioneer in precision genome engineering, today announced it has granted a Research License to Caravan Biologix, an innovator advancing mini-CAR™ technology: miniature T-cells that harness the body's natural immune power. The KOMbine™ Research License enables Caravan to evaluate KOMO’s high-efficiency targeted insertion technology platform for a predefined research period. Under the license agreement, Caravan will have access to t...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Crossbow Therapeutics, Inc., a biotechnology company developing T-Bolt™ therapies, a novel class of T-cell receptor (TCR)-mimetic antibody therapeutics, today announced the nomination of its second development candidate, CBX-663, for the treatment of a broad range of solid tumor and hematologic malignancies. The next-generation T-cell engager targets telomerase reverse transcriptase (TERT), a protein that drives tumor growth and is expressed in up to 95% of ca...